MLICM
VERV

Metropolitan Life Insurance Company (MetLife)’s Verve Therapeutics VERV Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-3,526
Closed -$46.8K – 2036
2024
Q1 		$46.8K Buy
3,526
+325
+10% +$4.31K ﹤0.01% 1438
2023
Q4 		$44.6K Hold
3,201
– – ﹤0.01% 1510
2023
Q3 		$42.4K Buy
3,201
+403
+14% +$6.49K ﹤0.01% 1502
2023
Q2 		$52.5K Hold
2,798
– – ﹤0.01% 1392
2023
Q1 		$40.3K Hold
2,798
– – ﹤0.01% 1519
2022
Q4 		$54.1K Hold
2,798
– – ﹤0.01% 1426
2022
Q3 		$96.1K Buy
2,798
+345
+14% +$11K ﹤0.01% 1035
2022
Q2 		$37.5K Hold
2,453
– – ﹤0.01% 1679
2022
Q1 		$56K Sell
2,453
-1,946
-44% -$55.6K ﹤0.01% 1532
2021
Q4 		$162K Hold
4,399
– – ﹤0.01% 2161
2021
Q3 		$207K Buy
+4,399
New +$259K ﹤0.01% 2042

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VERV Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Verve Therapeutics (VERV) in Q2 2024, closing a stake of 3,526 shares — an estimated $46.8K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VERV in Q3 2021 and held it in 11 quarters. The position peaked at $207K in Q3 2021. 166 funds tracked by Wall St. Rank hold VERV as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Verve Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 3,526 Verve Therapeutics shares in Q2 2024, an estimated $46.8K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Verve Therapeutics in Q3 2021 and held it in 11 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Verve Therapeutics position peaked at $207K in Q3 2021.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.